Ben Taylor - Exscientia Chief CFO
| EXAIDelisted Stock | USD 4.84 0.00 0.00% |
Insider
Ben Taylor is Chief CFO of Exscientia Ltd ADR
| Age | 47 |
| Phone | 44 18 6581 8941 |
| Web | https://www.exscientia.ai |
Exscientia Management Efficiency
The company has return on total asset (ROA) of (0.2122) % which means that it has lost $0.2122 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4643) %, meaning that it created substantial loss on money invested by shareholders. Exscientia's management efficiency ratios could be used to measure how well Exscientia manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| John Lewicki | Mereo BioPharma Group | 72 | |
| Michael Todisco | Kymera Therapeutics | 59 | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| John Vavricka | Atea Pharmaceuticals | 61 | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Michael Diem | Century Therapeutics | 53 | |
| Dr AB | Unity Biotechnology | 56 | |
| Elaine Caughey | Kymera Therapeutics | N/A | |
| Kevan Shokat | Revolution Medicines | N/A | |
| Mark Murcko | Relay Therapeutics | 64 | |
| Anirvan Ghosh | Unity Biotechnology | 60 | |
| Ahmed JD | Pieris Pharmaceuticals | 39 | |
| Gordon MD | Pieris Pharmaceuticals | N/A | |
| MBBS MD | Mereo BioPharma Group | 54 | |
| MBA MBA | Mereo BioPharma Group | 67 | |
| JD MBA | Blueprint Medicines Corp | 51 | |
| Bertrand Esq | Adaptimmune Therapeutics Plc | 57 | |
| Vijay Sabesan | Kymera Therapeutics | 52 | |
| MA MBA | Relay Therapeutics | 48 | |
| Christine Granfield | Leap Therapeutics | 56 | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
Management Performance
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 |
Exscientia ADR Leadership Team
Elected by the shareholders, the Exscientia's board of directors comprises two types of representatives: Exscientia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exscientia. The board's role is to monitor Exscientia's management team and ensure that shareholders' interests are well served. Exscientia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exscientia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Overington, Chief Officer | ||
| Eileen JenningsBrown, Chief Officer | ||
| Ben AshwellFryer, VP Fin | ||
| Parker Moss, Executive Development | ||
| Ben Taylor, Chief CFO | ||
| CBE DPHIL, CEO Founder | ||
| Nikolaus Krall, Executive Medicine | ||
| Dan Ireland, Executive Secretary | ||
| Heather Togwell, Operations Mang | ||
| Caroline Rowland, Chief Officer | ||
| Chris Thomas, VP People | ||
| Garry Pairaudeau, Chief Officer | ||
| MarieLouise MD, Interim Lead | ||
| FRSE DPHIL, CEO Founder | ||
| David Hallett, Interim Officer | ||
| Michael MD, Chief Officer | ||
| Margo Mosley, VP Operations | ||
| Richard Law, Chief Officer | ||
| Sara Sherman, Vice Relations |
Exscientia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exscientia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (10.66) % | ||||
| Current Valuation | 346.92 M | ||||
| Shares Outstanding | 130.82 M | ||||
| Shares Owned By Insiders | 25.90 % | ||||
| Shares Owned By Institutions | 20.80 % | ||||
| Number Of Shares Shorted | 2.81 M | ||||
| Price To Book | 1.95 X | ||||
| Price To Sales | 37.10 X |
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exscientia Ltd ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Other Consideration for investing in Exscientia Stock
If you are still planning to invest in Exscientia ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Exscientia's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |